{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:23:10Z","timestamp":1758050590217,"version":"3.44.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"am","delay-in-days":408,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bulcan.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T04:51:12Z","timestamp":1589518272000},"page":"800-812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pr\u00e9vention et traitement des naus\u00e9es et vomissements induits par les traitements anticanc\u00e9reux (NVITAC) en h\u00e9mato-oncologie p\u00e9diatrique\u00a0: mise \u00e0 jour"],"prefix":"10.1016","volume":"107","author":[{"given":"Marie","family":"Delmotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Mouffak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Mongaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Michelet-Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Roques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0365","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2165\/00003495-199753020-00003","article-title":"Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds","volume":"53","author":"Veyrat-Follet","year":"1997","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.bulcan.2020.03.015_bib0370","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0375","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cncr.21631","article-title":"Acute and delayed nausea and emesis control in pediatric oncology patients","volume":"106","author":"Holdsworth","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0380","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/djx250","article-title":"Validation of the symptom screening in pediatrics tool in children receiving cancer treatments","volume":"110","author":"Dupuis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.bulcan.2020.03.015_bib0385","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.26.9.1221","article-title":"Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents","volume":"26","author":"Dupuis","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.bulcan.2020.03.015_bib0390","doi-asserted-by":"crossref","first-page":"e27646","DOI":"10.1002\/pbc.27646","article-title":"Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline","volume":"66","author":"Paw Cho Sing","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0395","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0400","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/oxfordjournals.annonc.a057695","article-title":"Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis","volume":"1","author":"Martin","year":"1990","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/1097-0142(19950801)76:3<343::AID-CNCR2820760302>3.0.CO;2-V","article-title":"Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban)","volume":"76","author":"Morrow","year":"1995","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2020.03.015_bib0410","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/cncr.20718","article-title":"Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma","volume":"101","author":"Roscoe","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2020.03.015_bib0415","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","article-title":"Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model","volume":"64","author":"Pollera","year":"1989","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0420","first-page":"202","article-title":"Pharmacoth\u00e9rapie des naus\u00e9es et vomissements induits par la chimioth\u00e9rapie chez les enfants","volume":"39","author":"Marquis","year":"2006","journal-title":"Pharmactuel"},{"issue":"8","key":"10.1016\/j.bulcan.2020.03.015_bib0425","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pbc.25063","article-title":"Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients","volume":"61","author":"Dupuis","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2020.03.015_bib0430","first-page":"CD007786","article-title":"Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood","volume":"2","author":"Phillips","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.bulcan.2020.03.015_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199501053320101","article-title":"Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer","volume":"332","author":"Italian Group for Antiemetic Research","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2020.03.015_bib0440","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","article-title":"Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients","volume":"60","author":"Dupuis","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2020.03.015_bib0445","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","article-title":"Establishing the dose of the oral NK1\u00a0antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting","volume":"97","author":"Chawla","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0450","first-page":"951","article-title":"Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting","volume":"96","author":"Durand","year":"2009","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20020444","article-title":"Clinical use and molecular action of corticosteroids in the pediatric age","volume":"20","author":"Ferrara","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.bulcan.2020.03.015_bib0460","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/cid\/cis774","article-title":"Association between corticosteroids and infection, sepsis, and infectious death in pediatric acute myeloid leukemia (AML): results from the Canadian infections in AML research group","volume":"55","author":"Dix","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.bulcan.2020.03.015_bib0465","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/adc.65.8.822","article-title":"5-HT3\u00a0antagonist ondansetron--an effective outpatient antiemetic in cancer treatment","volume":"65","author":"Pinkerton","year":"1990","journal-title":"Arch Dis Child"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0470","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/0959-8049(96)00157-8","article-title":"An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5mg\/m2\u00a0with 10mg\/m2","volume":"32A","author":"Brock","year":"1996","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2020.03.015_bib0475","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/07357909909032871","article-title":"Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients","volume":"17","author":"Sandoval","year":"1999","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0480","first-page":"259","article-title":"[Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2\u00a0doses]","volume":"87","author":"Mabro","year":"2000","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0485","first-page":"680","article-title":"Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia","volume":"20","author":"Siddique","year":"2011","journal-title":"Mymensingh Med J"},{"issue":"9","key":"10.1016\/j.bulcan.2020.03.015_bib0490","first-page":"3091","article-title":"A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy","volume":"26","author":"Jain","year":"2018","journal-title":"Support Care Cancer"},{"issue":"19","key":"10.1016\/j.bulcan.2020.03.015_bib0495","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2217\/fon-2017-0189","article-title":"Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study","volume":"13","author":"Kov\u00e1cs","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.bulcan.2020.03.015_bib0500","doi-asserted-by":"crossref","first-page":"e26815","DOI":"10.1002\/pbc.26815","article-title":"Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy","volume":"65","author":"Tan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"10.1016\/j.bulcan.2020.03.015_bib0505","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","article-title":"American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006","volume":"24","author":"American Society of Clinical Oncology","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0510","first-page":"295","article-title":"[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]","volume":"86","author":"Mabro","year":"1999","journal-title":"Bull Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0515","first-page":"2917","volume":"23","author":"Karthaus","year":"2015","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0520","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MPG.0000000000001173","article-title":"Exposure-response of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients","volume":"63","author":"Wang","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0525","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MPH.0000000000001357","article-title":"Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial","volume":"41","author":"Chaudhary","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2020.03.015_bib0530","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jcph.322","article-title":"Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study","volume":"54","author":"Zuo","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0535","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14740338.2019.1568988","article-title":"Safety of clinical practive guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis","volume":"18","author":"Patel","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"22","key":"10.1016\/j.bulcan.2020.03.015_bib0540","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0545","first-page":"220","article-title":"Utilisation de l\u2019apr\u00e9pitant pour les naus\u00e9es et les vomissements r\u00e9fractaires secondaires \u00e0 la chimioth\u00e9rapie chez une adolescente","volume":"38","author":"Ouellet","year":"2005","journal-title":"Pharmactuel"},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0550","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pbc.20378","article-title":"Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents","volume":"45","author":"Smith","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0555","first-page":"127","article-title":"Aprepitant and fosaprepitant use in children and adolescents at an academic medical center","volume":"19","author":"Shillingburg","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0560","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pbc.21811","article-title":"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability","volume":"52","author":"Gore","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2020.03.015_bib0565","first-page":"3229","article-title":"Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Bakhshi","year":"2015","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0570","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3\u00a0trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0575","doi-asserted-by":"crossref","first-page":"e27273","DOI":"10.1002\/pbc.27273","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: an analysis by age group","volume":"65","author":"Kang","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0580","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0090-9556(24)15217-8","article-title":"Role of CYP2B6\u00a0and CYP3A4\u00a0in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes","volume":"27","author":"Granvil","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0585","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.bulcan.2020.03.015_bib0590","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-019-0840-0","article-title":"Latest update on prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"21","author":"Sherani","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bulcan.2020.03.015_bib0595","unstructured":"Vidal. (page consult\u00e9e le 23\/03\/20). PLITICAN\u00ae alizapride, [en ligne] http:\/\/vidal.aphp.fr\/showProduct.html?productId=13380."},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0600","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/clpt.1986.109","article-title":"The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial","volume":"39","author":"Joss","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0605","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2125.1994.tb04355.x","article-title":"Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study","volume":"38","author":"Seng","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2020.03.015_bib0610","unstructured":"Primperan et ses g\u00e9n\u00e9riques (m\u00e9toclopramide)\u00a0: actualisation des indications et de la posologie pour diminuer le risque d\u2019effets ind\u00e9sirables \u2013\u00a0Point d\u2019Information\u00a0\u2013 ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Primperan-et-ses-generiques-metoclopramide-Actualisation-des-indications-et-de-la-posologie-pour-diminuer-le-risque-d-effets-indesirables-Point-d-Information. Acc\u00e8s au site le 26\u00a0juillet 2019."},{"issue":"9","key":"10.1016\/j.bulcan.2020.03.015_bib0615","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/bcp.13630","article-title":"High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study","volume":"84","author":"Tsai","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.bulcan.2020.03.015_bib0620","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-017-2407-z","article-title":"Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase\u00ae","volume":"74","author":"Svendsen","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.bulcan.2020.03.015_bib0625","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40264-016-0418-9","article-title":"The safety of metoclopramide in children: a systematic review and meta-analysis","volume":"39","author":"Lau Moon Lin","year":"2016","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0630","first-page":"268","article-title":"A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1\u00a0trials design","volume":"14","author":"Nathan","year":"2006","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0635","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0640","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/pbc.25286","article-title":"Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review","volume":"62","author":"Flank","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0645","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00228-015-1982-0","article-title":"Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings","volume":"72","author":"Pozzi","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0650","first-page":"549","article-title":"Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study","volume":"26","author":"Flank","year":"2018","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0655","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia","volume":"20","author":"Grothe","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0660","first-page":"895","article-title":"Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ono","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2020.03.015_bib0665","doi-asserted-by":"crossref","first-page":"e26542","DOI":"10.1002\/pbc.26542","article-title":"Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update","volume":"64","author":"Patel","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2020.03.015_bib0670","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jand.2015.10.020","article-title":"Chemotherapy-induced nausea and vomiting: a narrative review to inform dietetics practice","volume":"116","author":"Marx","year":"2016","journal-title":"J Acad Nutr Diet"},{"issue":"11","key":"10.1016\/j.bulcan.2020.03.015_bib0675","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jnci\/93.11.810","article-title":"Behavioral intervention for cancer treatment side effects","volume":"93","author":"Redd","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/pbc.22778","article-title":"Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy","volume":"56","author":"Pillai","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0685","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/1043454218782133","article-title":"The use of aromatherapy to reduce chemotherapy-induced nausea in children with cancer: a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Evans","year":"2018","journal-title":"J Pediatr Oncol Nurs"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0690","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bulcan.2018.11.017","article-title":"[Complementary and alternative medicine use in two French pediatric oncology centers: a common practice]","volume":"106","author":"Menut","year":"2019","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0695","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/pr.2015.91","article-title":"Efficacy and safety of acupuncture in children: an overview of systematic reviews","volume":"78","author":"Yang","year":"2015","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.bulcan.2020.03.015_bib0700","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00520-005-0846-z","article-title":"Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology. Interim results of a multicenter crossover study","volume":"14","author":"Reindl","year":"2006","journal-title":"Support Care"},{"issue":"4","key":"10.1016\/j.bulcan.2020.03.015_bib0705","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1089\/acm.2011.0102","article-title":"Reduction in nausea and vomiting in children undergoing cancer chemotherapy by either appropriate or sham auricular acupuncture points with standard care","volume":"18","author":"Yeh","year":"2012","journal-title":"J Altern Complement Med"},{"issue":"6","key":"10.1016\/j.bulcan.2020.03.015_bib0710","doi-asserted-by":"crossref","first-page":"e1575","DOI":"10.1542\/peds.2011-1091","article-title":"The safety of pediatric acupuncture: a systematic review","volume":"128","author":"Adams","year":"2011","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.bulcan.2020.03.015_bib0715","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00148581-200305090-00003","article-title":"Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children","volume":"5","author":"Dupuis","year":"2003","journal-title":"Paediatr Drugs"},{"issue":"3","key":"10.1016\/j.bulcan.2020.03.015_bib0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1043454216688638","article-title":"Integrative therapeutic approaches for the management and control of nausea in children undergoing cancer treatment: a systematic review of literature","volume":"34","author":"Momani","year":"2017","journal-title":"J Pediatr Oncol Nurs"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120302009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120302009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:29Z","timestamp":1757791949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120302009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":72,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0007455120302009"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.03.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9vention et traitement des naus\u00e9es et vomissements induits par les traitements anticanc\u00e9reux (NVITAC) en h\u00e9mato-oncologie p\u00e9diatrique\u00a0: mise \u00e0 jour","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}